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Summary Radiolabelled meta-iodobenzylguanidine (MIBG) is selectively taken up by tumours of neuroendocrine origin, where its cellular
localization is believed to be cytoplasmic. The radiopharmaceutical [1311]MIBG is now widely used in the treatment of neuroblastoma, but other
radioconjugates of benzylguanidine have been little studied. We have investigated the cytotoxic efficacy of beta, alpha and Auger electron-
emitting radioconjugates in treating neuroblastoma cells grown in monolayer or spheroid culture. Using a no-carrier-added synthesis route,
we produced 1231-, 1251-, 1311- and 211At-labelled benzylguanidines and compared their in vitro toxicity to the neuroblastoma cell line SK-N-BE(2c)
grown in monolayer and spheroid culture. The Auger electron-emitting conjugates ([1231]MIBG and [1251]MIBG) and the alpha-emitting
conjugate ([211At]MABG) were highly toxic to monolayers and small spheroids, whereas the beta-emitting conjugate [1311]MIBG was relatively
ineffective. The Auger emitters were more effective than expected if the cellular localization of MIBG is cytoplasmic. As dosimetrically
predicted however, [211At]MABG was found to be extremely potent in terms of both concentration of radioactivity and number of atoms ml-'
administered. In contrast, the Auger electron emitters were ineffective in the treatment of larger spheroids, while the beta emitter showed
greater efficacy. These findings suggest that short-range emitters would be well suited to the treatment of circulating tumour cells or small
clumps, whereas beta emitters would be superior in the treatment of subclinical metastases or macroscopic tumours. These experimental
results provide support for a clinical strategy of combinations ('cocktails') of radioconjugates in targeted radiotherapy.
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Meta-iodobenzylguanidine (MIBG) is a structural analogue ofthe
neuroadrenergic blocking drugs bretylium and guanethidine. It is
selectively accumulated by an active mechanism in cells of neural
crest origin. Radiolabelled MIBG allows the scintigraphic imaging
of neural crest tumours (Weiland et al, 1980) and ['311]MIBG is
used in the treatment of neuroblastoma and phaeochromocytoma
(Hartmann et al, 1987; Mastrangelo, 1987; Schwabe et al, 1987;
Voute et al, 1988). Clinical experience since 1984 has demon-
strated its potential, with an objective response rate of 35% in
patients with progressive heavily pretreated disease (Hoefnagel,
1994). Clinical studies are now evaluating the role of ['311]MIBG
at an earlier stage in therapy, either as a first line treatment or in
combination with other treatment modalities (DeKraker et al,
1995; Gaze et al, 1995; Mastrangelo et al, 1995).
Although many patients show beneficial responses to
['311]MIBG treatment, a significant number subsequently relapse
from previously undetected tumour sites (Sisson et al, 1989). This
suggests that microtumours below the limit ofclinical detectability
have survived ['311]MIBG therapy. A possible explanation for the
relative sparing of micrometastases is related to the micro-
dosimetry of '3'I targeted radiation. '311 emits P particles with a
mean path length of 800 gm. Therefore, in addition to targeted
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cells, neighbouring cells will be irradiated by crossfire. In large
tumours, this may be advantageous, as underdosing due to hetero-
geneity ofuptake could be circumvented. However, as tumour size
decreases the fraction of energy absorbed by the tumour becomes
progressively smaller and more of the energy is deposited outside
the target (Humm, 1986). Mathematical modelling studies predict
that, for I'lI, the optimal diameter range for curability is 2.6-5.0
mm (Wheldon et al, 1991; O'Donoghue et al, 1995). Tumours
below this size are operationally resistant to 'I'I 3-emissions as the
fraction of energy they absorb is greatly reduced. Experimental
evidence supporting these predictions has been provided by our in
vitro investigation using a multicellular spheroid model (Gaze et
al, 1992) and independently by the recent studies of Weber et al
(1996). The possible sparing of small micrometastases by single-
agent ['311]MIBG provides a rationale for the incorporation of
['311]MIBG in combined-modality treatments (Gaze and Wheldon,
1996). In addition to underdosing of small tumour deposits, long-
range 3-emissions may also damage surrounding normal tissues. A
large proportion of the patients treated with ['311]MIBG suffer
significant haematological toxicity, which may be partially due to
radiation crossfire to haemopoietic cells from MIBG-targeted
neuroblastoma cells infiltrating the marrow (Gelfand, 1993).
Because of these limitations of 13'I, alternative radiohaloconju-
gates of benzylguanidine have been proposed. Short-range emit-
ters with therapeutic potential include 1231, 1251 and 211At. 1231 and
1251 decay by electron capture and internal conversion. These
processes result in the emission of low-energy 'Auger' electrons,
which have ultra-short range (< 1 gm) and are densely ionizing.
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Figure 1 Kinetics of uptake of MIBG and Nal in SK-N-BE(2c) and MCF-7
cells. M,MIBG uptake in SK-N-BE(2c); O, Nal uptake in SK-N-BE(2c); *,
MIBG uptake in MCF-7; 0, Nal uptake in MCF-7 cells
Auger electron emitters deposit highly localized energy, resulting
in severe damage to molecular structures in the immediate vicinity
of the decay site. This has important consequences for the treat-
ment of micrometastases. Firstly, the efficacy of Auger electron-
emitters will be unaffected by the same size constraints as 1311,
with the result that the energy they deposit will be more fully
absorbed in small tumour volumes. In addition, crossfire to adja-
cent non-target sites will be negligible, resulting in the sparing of
surrounding normal tissues.
['251I]MIBG has been shown to be toxic to neuroblastoma cells in
vitro (Bruchelt et al, 1988; Guerreau et al, 1990; Senekowitsch et
al, 1992). In contrast, in vivo data from mice bearing microscopic
disease demonstrated no difference in tumour survival between
control and ['25I]MIBG-treated animals (Rutgers et al, 1994).
Despite these conflicting laboratory findings, ['25I]MIBG has been
used to treat stage III and IV neuroblastoma patients with bone
marrow involvement with encouraging results (Sisson et al, 1990,
1991, 1996; Hoefnagel et al, 1991).
Another radiohalogen with potential for the treatment of
micrometastatic disease is 21'At. Its a-decay particles have a range
of 50-100 jm in tissues, corresponding to a few cell diameters.
These emissions have high linear energy transfer quality and
hence strong biological effectiveness. Several investigators have
shown that astatinated compounds are extremely toxic to experi-
mental neoplasms, including melanoma and osteosarcoma (Link
and Carpenter, 1992; Vergote et al, 1992; Larsen et al, 1994). In
addition, it has been shown to be a particularly effective means of
eradicating metastatic disease due to the short range and potency
of its a-particles (Link and Carpenter, 1990; Link et al, 1996). It
has been suggested that 21'At-labelled benzylguanidine (MABG)
may be effective in the treatment of neuroblastoma micrometas-
tases (Shapiro and Gross, 1987; Mairs et al, 1991). This radiophar-
maceutical has been synthesized, and its uptake and toxicity have
been characterized in vitro (Vaidyanathan and Zalutsky, 1992;
Strickland et al, 1994). With respect to kinetics of accumulation
and retention MABG was identical to MIBG. However, MABG
was much more toxic to neuroblastoma cells than MIBG.
The advent of chemical syntheses that produce no-carrier-added
(n.c.a) radiohalogenated benzylguanidines (Vaidyanathan and
Figure 2 Clonogenic survival of SK-N-BE(2c) monolayers after [1231]-, [1251]-
and [1311]MIBG treatment. Cells were treated as described in Materials and
methods. Means ± s.d. of three observations. *, ['311]MIBG; *, ['231]MIBG; A,
[1251]MIBG
Zalutsky, 1993) has facilitated the evaluation of the potential of
short-lived radionuclides such as 123I and 21'At for neuroblastoma
therapy. We therefore undertook a comprehensive in vitro study in
neuroblastoma cell monolayers and multicellular spheroids to
examine the toxicity offour different n.c.a preparations ofbenzyl-
guanidine: [1231]MIBG, [251I]MIBG, [3111]MIBG and [211At]MABG.
MATERIALS AND METHODS
Cell lines
The human neuroblastoma cell line SK-N-BE (2c) was used for
these studies. This cell line was derived from the bone marrow ofa
patient with progressive neuroblastoma following treatment with
radiotherapy and chemotherapy (Beidler et al, 1978). The MCF-7
cell line was used as a negative control. This is a human breast cell
line derived from the pleural effusion of a breast carcinomapatient
(Soule et al, 1973).
Culture conditions
Cells were cultured in RPMI-1640 medium supplemented with
10% fetal bovine serum, penicillin/streptomycin (100 IU ml-'),
fungizone (2 jg ml-') and glutamine (200 mM) (all Gibco, Paisley,
UK). Cells were grown in a 5% CO2 atmosphere at 37°C.
No-carrier-added synthesis of radiohaloanalogues of
MIBG
Chemicals were purchased from Aldrich Chemical Company
(Dorset, UK). HPLC-grade solvents were obtained from Rathbum
Chemicals (Peebleshire, UK). Carrier-free sodium [1311]iodide and
sodium [1251]iodide were purchased from Amersham International
(Buckinghamshire, UK). Cafrier-free sodium [123f]iodide was
purchased from Cygne (Holland). No-carrier-added MIBG was
synthesized by iododesilyilation of trimethylsilylbenzylguanidine
(Vaidyanathan andZalutsky, 1993) andpurifiedby HPLC and solid-
phase extraction (Mairs et al, 1994a). [211At]MABG was synthe-
sized as previously described (Vaidyanathan and Zalutsky, 1992).
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Kinetics of MIBG uptake in SK-N-BE(2c) and MCF-7
cells
To determine the appropriate incubation period for cytotoxicity
studies, experiments were undertaken to determine the kinetics of
uptake of MIBG and sodium iodide (Nal). Cells were seeded in
six-well plates at an initial density of 0.5 x 105 cells and cultured
for 48 h. They were then assayed for MIBG or Nal uptake at
30-min intervals for a 5-h period. For the determination of
MIBG incorporation, the cells were incubated with 7 kBq of
['311]MIBG (specific activity 45-65 MBq mg-', Dupont Radio-
pharmaceuticals, Hertfordshire, UK). Non-specific uptake was
measured in the presence of 1.5 mM desmethylimipramine (DMI)
(Sigma-Aldrich, Dorset, UK). For Nal uptake, the cells were incu-
bated with 7 kBq of ['311]NaI (Amersham International, UK). After
incubation for the appropriate time, medium was removed, the
cells were washed with phosphate-buffered saline (PBS) and
radioactivity was extracted using two aliquots of 10% (w/v)
trichloroacetic acid. The activities of the extracts were then
measured in a gamma-well counter. Specific uptake of MIBG,
expressed as c.p.m. per 105 cells, was calculated by subtracting
values obtained in the presence ofDMI from total uptake.
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Figure 3 Effect of non-specific irradiation on clonogenic survival of SK-N-
BE(2c) monolayers. Cells were incubated with the indicated unconjugated
sodium iodide species as described in Materials and methods. Means ± s.d.
of three observations. 0, [1311] Nal; *, [1231] Nal; A, ['251] Nal
Clonogenic assays
Cells were seeded in 25-cm2 flasks at 2.5 x 105 cells per flask.
After 2 days, medium was removed and replaced with 4 ml of
fresh medium containing the appropriately labelled benzylguani-
dine at the desired radioactivity concentration. After incubation for
2 h, medium was removed and the cells were washed three times
with PBS. Cells were then trypsinized and counted. For each
radioactivity concentration, three flasks were seeded at 1000 cells
per flask. For greater radioactive concentrations (> 400 kBq ml-'),
additional flasks were seeded at higher cell numbers to compen-
sate for the potential increase in toxicity. Flasks were equilibrated
with 5% carbon dioxide and then incubated at 37°C. After 14
days, medium was removed and the colonies were fixed and
stained with carbol fuchsin. Colonies of more than 50 cells were
counted using an automated colony counter (Artek Systems
Corporation).
Spheroid studies
In this study, we used two sizes of spheroid of approximately
240 ,um and 400 iim diameter. These were grown by the contin-
uous stirring of3 x 106 SK-N-BE(2c) cells in Techne stirrer flasks.
Visible spheroids developed in 4-6 days.
For cytotoxicity studies, aliquots of spheroids of the required
diameter were transferred to 20-ml universal containers and
suspended in 1 ml of RPMI containing the appropriate concentra-
tion ofradiolabelled drug. Spheroids were then incubated for 2 h at
37°C. This incubation time was chosen because it has previously
been shown that MIBG accumulation by spheroids is close to
maximal after 2 h (Mairs et al, 1991). The medium was then
removed and the spheroids washed three times with PBS.
Spheroids were then transferred to Petri dishes and individually
pipetted into agar-coated wells containing 1 ml of RPMI medium.
One 24-well plate was used per treatment. These were incubated at
37°C in a 5% carbon dioxideatmosphere. Growth ofthe spheroids
was monitored over the next 2-3 weeks by measurement of their
cross-sectional area using a semiautomated image analysis system
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Figure 4 Clonogenic survival after [1231]-, [1251]- and [1311]MIBG treatment
of MCF-7 cells, which do not express the noradrenaline transporter.
0, [1311]MIBG; *, [1231]MIBG; A, [1251]MIBG
coupled via a television camera to a microscope. From these
measurements the median volume ofthe spheroids was calculated
to allow the construction ofspheroid regrowth curves.
RESULTS
Kinetics of uptake of MIBG and Nal in SK-N-BE(2c) and
MCF-7 cells
Preliminary experiments were undertaken to determine the rate of
uptake of MIBG and Nal in SK-N-BE(2c) and MCF-7 cells. As
Figure 1 shows, accumulation of MIBG by neuroblastoma cells
was maximal after about 2 h. This incubation period was used in
all subsequent experiments. MCF-7 cells demonstrated no ability
to actively accumulate MIBG overthe time period studied. Neither
cell line showed any accumulation ofNal.
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Figure 5 Growth curves of 240 gm-diameter SK-N-BE(2c) spheroids after treatment with (A) ['231]MIBG, (B) ['251]MIBG, (C) ['3l1]MIBG and (D) [2'At] MABG.
0, control; 0, 0.1 MBq ml-'; Ob 1 MBq ml-'; 2 MBq ml-'; A, 3 MBq ml-'; *, 4 MBq ml'. For MABG control; 0, 0.24 kBq ml-'; O, 0.48 kBq ml-';
0.74 kBq ml-'; A, 1.24 kBq ml-'; O, 1.51 kBq ml. The ordinate is the common logarithim of the spheroid volume in units of (gm)3. Each point represents the
median of 24 measurements
Effect of [1231]-, [1251]- and [1311]MIBG on SK-N-BE(2c)
neuroblastoma monolayers
Clonogenic assays of neuroblastoma cell monolayers demon-
strated that the two Auger-emitting conjugates were more toxic to
neuroblastoma cells than '3'I-labelled drug (Figure 2). Even at
radioactive concentrations of 1000 kBq ml', the surviving
fraction for '3'I-labelled material was only 0.4. In contrast,
using ["231]MIBG, a 1 log cell kill was achieved at a concentration
of 600 kBq ml-'. ['251]MIBG was even more potent than
['231]MIBG. 1 log cell kill was apparent after exposure to approxi-
mately 300 kBq ml' drug. It should be noted that the expression
activity per ml does not give any information about the absorbed
dose to cells. Consequently, no inference can be made about the
shape of these survival curves and the type of radiation to which
these cells have been exposed.
To control for the effects of non-specific irradiation by the
isotopes used, monolayers were incubated with identical activities
of unconjugated radioactive sodium iodides for 2 h. As Figure 3
shows, none ofthese was toxic. In addition, to demonstrate that the
observed toxicity was the result of specific uptake of the labelled
drug, the cell line MCF-7 was used as a negative control. This cell
line does not express the noradrenaline transporter (Mairs et al,
1994b) and consequently has no capacity for active uptake of
MIBG (see Figure 1). Again, none of the species tested caused
inhibition of colony formation (Figure 4). It is concluded that the
observed toxicity to neuroblastoma cells was due to the specific
incorporation of labelled MIBG.
Effect of [1231]-, [1251], [1311]MIBG and [211At]MABG on
small (240 gm) neuroblastoma spheroids
The relative effectiveness of the radiolabelled MIBG analogues
was also determined using small (240 jim) spheroids.
Determination of efficacy was derived from the regrowth part of
the volume vs time plot (Wheldon et al, 1985). A result similar to
British Journal of Cancer (1998) 77('12), 2061-2068
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that obtained with cell monolayers was observed. Both [1'31]MIBG
and ['211]MIBG inhibited spheroid growth in a dose-dependent
manner. [1251]MIBG was the more effective radiopharmaceutical
when compared on a radioactivity per ml basis: growth inhibition,
defined as failure to regrow after 20 days, was apparent at 0.1
MBq ml-' [1211]MIBG, whereas 1 MBq ml-l [123I]MIBG was
required to achieve a similar effect. ['311]MIBG was again the least
effective of the iodinated conjugates - significant growth delay
was only apparent at a concentration of3 MBq ml-'. [21 At]MABG
was the most toxic of all the conjugates investigated: treatment
with 0.48 kBq ml' was sufficient to inhibit growth (Figure 5).
Effect of [1231]-, [1251]- and [1311]MIBG on large (400 gim)
neuroblastoma spheroids
In contrast to the toxic effects of ['231]MIBG and ['211]MIBG on
monolayer and small spheroids, 1231- and 1251-labelled conjugates
were completely ineffective in the treatment of large (400 gm)
spheroids. At the radioactive concentrations tested, no inhibition
ofgrowth was observed and all spheroids regrew at rates similar to
controls. Conversely, ['311]MIBG induced growth inhibition at
concentrations greater than MBq ml' (Figure 6).
To control for the effects of non-specific irradiation, spheroids of
both sizes were incubated with 4 MBq mlr' of the appropriate
radioactive sodium iodide. Forthe MABG studies, control spheroids
were incubated with 9.5 kBq ml' of sodium astatide. No growth
inhibition was observed in any ofthe spheroids (data not shown).
DISCUSSION
These results describe the comparative cytotoxic efficacies of
alpha, beta and Auger electron-emitting radioconjugates of the
targeting agent MIBG using a neuroblastoma cell line grown in
monolayer and spheroid culture. Our findings clearly demonstrate
a relationship between the physical characteristics ofradionuclides
and their therapeutic effectiveness in experimental in vitro therapy
(Table 1). The Auger electron-emitting conjugates of MIBG
(['231]MIBG and ['211]MIBG) were capable of killing single cells
and small spheroids. However, their toxicity was reduced in larger
target volumes. Incomplete drug penetration and lack of crossfire
probably account for the absence of growth inhibition in the
400 ,um spheroids after exposure to ['231]MIBG or ['251]MIBG.
Incomplete penetration of MIBG in neuroblastoma spheroids
whose diameter exceeds 400 ,um has previously been documented
(Mairs et al, 1991). Therefore, ['231]MIBG and [1251]MIBG may
have been toxic only to the outer, metabolically most active, cell
layers. Adjacent untargeted cells would have continued to prolif-
erate since they experienced no crossfire from their targeted neigh-
bours. Consequently, growth would be unaffected. [21 'At]MABG
has already been shown to be significantly more toxic than
['311]MIBG to neuroblastoma cell monolayers (Strickland et al,
1994). The results presented here confirm this effect in small
spheroids. Its efficacy in large spheroids was not determined.
For the long-range j-emitting conjugate (['311]MIBG), the size
dependence of toxicity was opposite to that of ['231]MIBG and
['251]MIBG, i.e. small spheroids were less vulnerable to
['3'I]MIBG than large ones. This may be due to the dissipation of
more f-decay energy outside small target volumes, as predicted
from microdosimetric considerations (Wheldon et al, 1991;
O'Donoghue et al, 1995) and in agreement with previous experi-
mental findings (Gaze et al, 1992). This explanation is supported
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Figure 6 Growth curves of 400 gm-diameter SK-N-BE(2c) spheroids after
treatment with (A) ['231]MIBG, (B) ['251]MIBG and (C) ['3'1]MIBG. 0, Control;
0, 0.1 MBq ml-'; O 1 MBq ml-';M,2 MBq ml-'; A, 3 MBq ml-'; *, 4 MBq
ml'. The ordinate is the common logarithm of the spheroid volume in units of
(pm)3. Each point represents the median of 24 measurements
by the results of our data obtained from monolayer studies which
indicated that, of the radioiodine isotopes examined, I''I was the
least effective inhibitor ofcolony formation. Because ofthe planar
geometry of cellular monolayers, most of the decay energy would
have been deposited above and below the plane ofthe cells.
These findings are in agreement with the results of a recent
study by Weber et al (1996), who compared the therapeutic effec-
tiveness of '3'I and '211-labelled MIBG in neuroblastoma spheroids.
Using a mathematical model, the radiation dose rates within small
spherical tumours could be calculated. These calculations predict
that higher mean dose rates can be achieved by ['211]MIBG than
[':II]MIBG in tumour diameters up to 100 gm. However, in larger
tumours, the mean dose rates achieved by '3ll-labelled MIBG
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Table 1 Relative toxicity of alternative radionuclides conjugated to
benzylguanidine
Radiolabel Radiotoxicitya
Monolayer Small spheroid Large spheroid
1311 + + ++
1231/1251 ++ ++ 0
21'At ...+++b ... ND
aNumber of + signs allow comparison of rank order of inhibitory potency
within columns or rows. They do not indicate proportional effectiveness. 0
indicates absence of growth inhibition at the concentrations of radioactivity
used in this study. bToxicity of 21At to cells grown in monolayer taken from
Strickland et al, 1994. ND, not determined.
Table 2 Comparison of the toxicities of radionuclide conjugates of MIBG in
terms of administered radioactivity in kBq ml-'
Endpoint Activity (kBq ml-')
required to achieve end point
21'At 1231 1251 1311
Clonogenic survivala 0.22 480 300 -
Spheroid regressionb 1.37 1414 320 3460
aSurvival fraction of 0.1. bNo spheroid regrowth by 20 days.
Table 3 Comparison of the toxicities of radionuclide conjugates of MIBG in
terms of number of atoms ml-1
Endpoint No of atoms x 1010 required
to achieve end point
21'At 1231 1251 1311
Clonogenic survivala 0.0009 3.50 230 -
Spheroid regressionb 0.00513 9.68 241 346
aSurvival fraction of 0.1. bNo spheroid regrowth by 20 days.
would be up to eightfold higher. These predictions were borne out
by in vitro experiments, which found ['251]MIBG to be superior to
[1311I]MIBG in treating small spheroids but that, as spheroid size
increased, this advantage was lost and ['311I]MIBG became the
more effective radiopharmaceutical.
To allow aquantitative comparison ofthe relative effectiveness of
each isotope, the dose in kBq ml and in atoms ml was calculated
for each analogue of MIBG. As Table 2 indicates, on a kBq ml
basis, [21"At]MABG was substantially more toxic than any of the
radioiodinated species. Ofthe iodinated MIBG molecules, the rank
order oftoxicity was 1251> 1231 > I3'l. On conversion ofthese activi-
ties to the number of atoms present per ml, 21'At remains the most
toxic; however, 1231 rather than 1251 was the most effective iodine
species (Table 3). These calculations highlight the potential of 1231
over 1251 for targeted radiotherapy. Although it is less efficient in the
production ofDNA double-strand breaks [0.74 compared with 1.00
per cell perdecay for 1251 (Makrigiorgos et al, 1992)], the number of
atoms of 1231 present in a given activity is approximately 100-fold
fewer. Therefore, significantly lower molar amounts of ['231]MIBG
would be required to deliver a dose of targeted radiation. It is
predicted that the administration of low concentrations of MIBG
should decrease passive, relative to active, drug uptake, thereby
enhancing thetherapeutic ratio (Mairs etal, 1995). Furthermore, the
number of radioactive atoms administered should be as low as
possible to minimize the dose to normal organs that are capable of
uptake with long-term retention (e.g. thyroid).
The results of this in vitro study suggest that short-range conju-
gates of MIBG could be effective in the treatment of metastatic
neuroblastoma. A prerequisite to examining theirpotential in vivo
is the availability of a realistic murine model of micrometastatic
neuroblastoma. Recent studies using severe combined immune
deficient (SCID) mice have demonstrated dissemination ofhuman
neuroblastoma cells to the liver, adrenal glands and bone marrow.
Metastases in different organs had characteristic histopathology,
and those in the bone marrow presented as syncytia-like cell
aggregates - features typically seen in patients (Bogenmann,
1996). Such a model could be used to investigate the efficacy of
1231I, 1251- and 2I'At-labelled benzylguanidine conjugates in vivo.
The observation that Auger electron emitters conjugated to
benzylguanidine are capable of killing SK-N-BE(2c) neuroblas-
toma cells raises important questions about the subcellular loca-
tion ofMIBG and the mechanism ofcell death. Several hypotheses
could explain these results. MIBG may localize in the nucleus of
neuroblastoma cells. It is also possible that there are other sub-
cellular targets for Auger electrons, such as the mitochondria.
Alternatively, particles other than Auger electrons emitted during
the decay of 1231 and 1251 may have sufficient range to penetrate into
the nucleus of a targeted cell. A fourth possibility is that MIBG
labelled with Auger electron emitters mediates cell kill through
apoptosis triggered by a novel mechanism.
The conventional opinion is that the critical cellular target for
ionizing radiation damage is nuclear DNA. Therefore, ultra-short-
range radionuclides, such as Auger electron emitters, should be
toxic only if delivered to the nucleus of the target cell (Charlton,
1986). This has been confirmed by in vitro studies - using extra-
cellular Na'251, cytoplasmic [1251]iododihydrorhodamine and
nuclear '25IUdR - which demonstrated that significanttoxicity was
associated only with the nuclear located 1251 (Kassis et al, 1987).
Similar results have also been observed in vivo by Link and
colleagues, who compared the therapeutic efficacy of 1251 and
21'At-labelled methylene blue to treat mice bearing malignant
melanoma. Only 21'At-labelled methylene blue produced signifi-
cant therapeutic effects. As the subcellular fate of this targeting
agent is cytoplasmic, it was concluded that '251-labelled methylene
blue was too far away from the genome to produce cytotoxicity
(Link et al, 1989). Although subcellular localization studies have
demonstrated that MIBG concentrates mainly in the cytoplasm of
neuroblastoma cells (Gaze et al, 1991; Clerc et al, 1993), the fixa-
tion procedures employed in these studies may have caused a
redistribution of the drug (Smets et al, 1991). The demonstration
that significant cell kill can be achieved with 1251 or '231-labelled
MIBG could represent evidence for a nuclear localization of
MIBG. The amount of drug accumulated at this site may be
undetectable by conventional means but nevertheless capable of
delivering a toxic dose of radiation to the cell nucleus.
Alternatively, MIBG conjugated to Auger electron emitters
could be cytotoxic through damage to the mitochondria.
Subcellular localization studies have identified mitochondria as
sites ofMIBG accumulation (Gaze et al, 1991). Mitochondrial toxi-
city could result from disruption of inner mitochondrial membrane
proteins or by direct effects on the mitochondrial genome. Indeed,
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mitochondrial DNA is susceptible to radiation damage because of
its limited capacity for repair (Tritschler and Medori, 1993).
It is also conceivable that some particles emitted during the
decay of 1231 and 12'5 may have sufficient range to reach genomic
DNA ofa targeted cell despite cytoplasmic or perinuclear localiza-
tion. Although the entire Auger and Coster-Kronig electron
spectra for these radionuclides have not been measured experi-
mentally, calculations using theoretical transition rates and ener-
gies indicate that both isotopes emit some electrons with ranges of
the order of the radius of a mammalian cell (Howell, 1992; Sastry,
1992). Assuming a cytoplasmic location for MIBG, it is possible
that such emissions would deliver significant doses ofradiation to
the nucleus. However, this possibility is not supported by the
classical experiments of Kassis and colleagues described earlier
(Kassis et al, 1987).
A more exotic possibility is that Auger electron irradiation of
cytoplasmic targets achieves cell kill by an indirect route, such as
the triggering ofapoptosis in susceptible cells. Some workers have
reported that apoptosis-mediated cell death may result from
membrane damage and the consequent generation of ceramide
(Jarvis et al, 1994; Obeid et al, 1994) and that this process may
be initiated by ionizing radiation damage to cell membranes
(Haimovitz-friedman, 1994). We intend to investigate this possi-
bility using DNA-targeted or cell-membrane-targeted Auger emit-
ters (1251 incorporated in IUDR or conjugated to concanavilin A) to
treat neuroblastoma cells which differ in their capacity for apo-
ptosis and expect to be able to determine the role of membrane
irradiation in radiation cell killing in apoptosis competent cells.
These experiments should provide a definitive evaluation of the
role ofapoptosis and ofmembrane irradiation in cell kill by Auger
electron-emitters.
Whatever the detailed mechanisms, it is clear that these alterna-
tive isotopes have potential in the treatment of neuroblastoma.
Short-range Auger electron emitters are suited to the treatment of
single cells or small clumps and longer range 3-emitters to larger
cell masses. Alpha-emitters are of very high molecular potency in
treating single cells or small neuroblastoma spheroids, though
their efficacy in the treatment of larger cellular aggregates is not
yet evaluated. These results suggest that 'combination cocktails'
of radionuclides may be beneficial in the treatment of dissemi-
nated cancer where a targeting agent exists for which alternative
radioconjugates can be made. Benzylguanidine targeting of radio-
halogens to neuroblastoma cells may be the first example of a
strategy with wide application in targeted radiotherapy.
CONCLUSION
The experiments reported demonstrate the theoretically expected
relationships between radiotoxicity, radionuclide emission charac-
teristics and the geometrical configuration of the target cell kill
population, while posing some questions about mechanisms ofcell
kill by Auger electron emitters. These results suggest that the
combined use of short-range and long-range particle-emitting
radionuclide conjugates of benzylguanidine could enhance the
therapeutic efficacy of targeted radiotherapy in neuroblastoma
patients with disseminated disease.
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